BACKGROUND: Long-term oxygen therapy (LTOT) is sometimes prescribed for patients with advanced lung cancer who are potential candidates for chemotherapy. The aim of this study was to assess the usefulness of chemotherapy for patients with this disease who require LTOT. METHODS: The medical records of 40 patients with advanced lung cancer who received LTOT while undergoing systemic chemotherapy at our institution between January 2009 and December 2014 were retrospectively reviewed. Chemotherapy consisted of cytotoxic or molecular-targeted agents. RESULTS: Twenty-four patients had adenocarcinoma, 6 had squamous cell carcinoma, and 10 had small cell lung cancer (SCLC). The median survival time from the date of the first chemotherapy cycle performed in conjunction with LTOT was 194 days. In a multivariate analysis, the only factor significantly associated with better prognosis was the line (first or second) of the first chemotherapy with LTOT (hazard ratio =0.42; 95% confidence interval, 0.18 to 0.94). Among the 40 patients, 10 (25%) received chemotherapy during the last 30 days of their lives, 2 of whom died of chemotherapy-related adverse events. CONCLUSIONS: Chemotherapy for patients with advanced lung cancer who receive LTOT may be acceptable if it is the first- or second-line treatment. However, we should be mindful of the potential overuse of chemotherapy and its negative impact on quality of life.
BACKGROUND: Long-term oxygen therapy (LTOT) is sometimes prescribed for patients with advanced lung cancer who are potential candidates for chemotherapy. The aim of this study was to assess the usefulness of chemotherapy for patients with this disease who require LTOT. METHODS: The medical records of 40 patients with advanced lung cancer who received LTOT while undergoing systemic chemotherapy at our institution between January 2009 and December 2014 were retrospectively reviewed. Chemotherapy consisted of cytotoxic or molecular-targeted agents. RESULTS: Twenty-four patients had adenocarcinoma, 6 had squamous cell carcinoma, and 10 had small cell lung cancer (SCLC). The median survival time from the date of the first chemotherapy cycle performed in conjunction with LTOT was 194 days. In a multivariate analysis, the only factor significantly associated with better prognosis was the line (first or second) of the first chemotherapy with LTOT (hazard ratio =0.42; 95% confidence interval, 0.18 to 0.94). Among the 40 patients, 10 (25%) received chemotherapy during the last 30 days of their lives, 2 of whom died of chemotherapy-related adverse events. CONCLUSIONS: Chemotherapy for patients with advanced lung cancer who receive LTOT may be acceptable if it is the first- or second-line treatment. However, we should be mindful of the potential overuse of chemotherapy and its negative impact on quality of life.
Authors: Corey Langer; Sigui Li; Joan Schiller; William Tester; Bernardo L Rapoport; David H Johnson Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: F Barlesi; A Scherpereel; V Gorbunova; R Gervais; A Vikström; C Chouaid; A Chella; J H Kim; M J Ahn; M Reck; A Pazzola; H T Kim; J G Aerts; C Morando; A Loundou; H J M Groen; A Rittmeyer Journal: Ann Oncol Date: 2014-02-27 Impact factor: 32.976
Authors: Derek Grose; David S Morrison; Graham Devereux; Richard Jones; Dave Sharma; Colin Selby; Kirsty Docherty; David McIntosh; Marianne Nicolson; Donald C McMillan; Robert Milroy Journal: Lung Cancer Date: 2014-11-29 Impact factor: 5.705
Authors: John D Hainsworth; David R Spigel; Cindy Farley; Dianna L Shipley; James D Bearden; Jitendra Gandhi; Gerry Ann Houston; F Anthony Greco Journal: Cancer Date: 2007-11-01 Impact factor: 6.860